I am sure Amgen and Orbimed are looking over bom shoulder ensuring their investment brings returns in longterm. The only other scenario in play would be an Amgen takeover, but i think for long term success unilife needs to be independent of Amgen as it makes dealing with them more appealing to Amgen's competitors. Imo best to be cautiously optimistic.
Add to My Watchlist
What is My Watchlist?